SCHEMBL6745795

SCHEMBL6745795

CS(=O)(=O)CCc1ccc2cc[nH]c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 1/20 0.53
▸ BACE1 P56817 4/20 0.50
▸ MEN1 O00255 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CYP2A6 P11509 1/20 0.41
▸ AHR P35869 3/20 0.41
▸ CMA1 P23946 1/20 0.41
▸ TYR P14679 1/20 0.41
▸ NLRP3 Q96P20 3/20 0.40
▸ ESR1 P03372 2/20 0.40
▸ CYP19A1 P11511 1/20 0.40
▸ HTR6 P50406 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ENPP2 Q13822 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ PIP4K2A P48426 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28853829 0.87 PTGS2 (0.53) PTGS2BACE1CYP2A6AHRCYP19A1
SCHEMBL3791740 0.78 BACE1 (0.53) BACE1MEN1POLBMAPK1KMT2A
SCHEMBL23245901 0.76 PTGS2 (0.51) PTGS2MEN1POLBKMT2ACYP2A6
SCHEMBL31329474 0.76 PTGS2 (0.51) PTGS2MEN1POLBKMT2ACYP2A6
SCHEMBL28853730 0.75 MEN1 (0.53) BACE1MEN1POLBMAPK1KMT2A
SCHEMBL3794968 0.75 BACE1 (0.50) BACE1MEN1POLBMAPK1KMT2A
SCHEMBL6743883 0.74 BACE1 (0.53) BACE1MEN1POLBMAPK1KMT2A
SCHEMBL1253355 0.74 BACE1 (0.56) BACE1MEN1POLBMAPK1KMT2A
SCHEMBL28220312 0.74 BACE1 (0.53) BACE1MEN1POLBMAPK1KMT2A
SCHEMBL27491214 0.74 BACE1 (0.53) BACE1MEN1POLBMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-08-26 — — US disclosed
US-6716837-B1 INDOLE AND INDAZOLE COMPOUNDS NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-04-06 — — US disclosed
EP-1196380-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS Allelix Corp. (CA) 2002-04-17 — — EP disclosed
WO-2001005758-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS ALLELIX CORP. (CA) 2001-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine SCN7A, CNR2, HTR7 PTGS2 591/4885BACE1 706/4885MEN1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback